Abstract The dual activation of glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) has emerged as a promising therapeutic strategy for managing type 2 diabetes and obesity. Tirzepatide. a dual agonist peptide. has exhibited superior clinical efficacy in glycemic and weight control compared to selective GLP-1R agonists. https://oznicoes.shop/product-category/m-jacket/